Summit Therapeutics Inc’s recent filing unveils that its Director Xia Yu acquired Company’s shares for reported $10.0 million on Oct 21 ’25. In the deal valued at $18.74 per share,533,617 shares were bought. As a result of this transaction, Xia Yu now holds 32,057,147 shares worth roughly $616.46 million.
Then, DUGGAN ROBERT W bought 26,680 shares, generating $499,983 in total proceeds. Upon buying the shares at $18.74, the Co-Chief Executive Officer now owns 76,680 shares.
Before that, Zanganeh Mahkam bought 26,680 shares. Summit Therapeutics Inc shares valued at $499,983 were divested by the Co-Chief Executive Officer at a price of $18.74 per share. As a result of the transaction, Zanganeh Mahkam now holds 76,680 shares, worth roughly $1.47 million.
Barclays initiated its Summit Therapeutics Inc [SMMT] rating to an Underweight in a research note published on September 17, 2025; the price target was $13. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Piper Sandler began covering SMMT with “Neutral” recommendation on August 19, 2025. UBS started covering the stock on July 01, 2025. It rated SMMT as “a Buy”.
Price Performance Review of SMMT
On Tuesday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock fall -1.18% to $19.23. Over the last five days, the stock has gained 2.61%. Summit Therapeutics Inc shares have fallen nearly -1.18% since the year began. Nevertheless, the stocks have risen 7.76% over the past one year. While a 52-week high of $36.91 was reached on 04/24/25, a 52-week low of $15.55 was recorded on 04/07/25.
Levels Of Support And Resistance For SMMT Stock
The 24-hour chart illustrates a support level at 18.92, which if violated will result in even more drops to 18.61. On the upside, there is a resistance level at 19.65. A further resistance level may holdings at 20.07.
How much short interest is there in Summit Therapeutics Inc?
A steep rise in short interest was recorded in Summit Therapeutics Inc stocks on 2025-10-15, growing by 58078.0 shares to a total of 32.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 32.21 million shares. There was a rise of 0.18%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 11, 2025 when Leerink Partners began covering the stock and recommended ‘”an Underperform”‘ rating along with a $12 price target.
